Comorbidities in sickle cell disease by age in the Indiana sickle cell data collection (IN-SCDC).

IF 2 4区 医学 Q3 HEMATOLOGY
Hematology Pub Date : 2026-12-31 Epub Date: 2026-04-07 DOI:10.1080/16078454.2026.2655477
Jennifer L Gatz, Amanda Okolo, Isaac A Janson, Brandon Hardesty, Brian E Dixon
{"title":"Comorbidities in sickle cell disease by age in the Indiana sickle cell data collection (IN-SCDC).","authors":"Jennifer L Gatz, Amanda Okolo, Isaac A Janson, Brandon Hardesty, Brian E Dixon","doi":"10.1080/16078454.2026.2655477","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Survival for individuals with sickle cell disease (SCD) is increasing, and along with it the potential for comorbid conditions that may be caused by cumulative tissue damage. This paper examines the prevalence of comorbidities among individuals with SCD in Indiana and assesses how these vary by age group.</p><p><strong>Methods: </strong>Data from the Indiana Sickle Cell Data Collection program (2015-2021) were used to identify confirmed and probable SCD cases. Comorbidities-asthma, avascular necrosis, stroke, retinopathy, moyamoya disease, and sickle nephropathy-were identified using ICD-9/10 codes.</p><p><strong>Results: </strong>Among the 1689 individuals, the 0-17 age group was the largest (42.9%). Asthma was the most common comorbidity (23.7%), highest in the 18-39 age group. Avascular necrosis, stroke, and retinopathy increased with age, while moyamoya was most common in youth. Logistic regression showed increasing age was associated with the risk of any comorbidity risk.</p><p><strong>Discussion: </strong>This study confirmed a high comorbidity burden among individuals with SCD, and that the risk of having any of the examined comorbidities increased with age. Findings align with national data, though differences in asthma and stroke prevalence highlight the impact of data sources and population characteristics.</p><p><strong>Conclusion: </strong>These results support the need for age-specific, multidisciplinary care strategies and provide valuable insights for clinicians, policymakers, and public health officials to improve outcomes and allocate resources effectively for the SCD population.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2655477"},"PeriodicalIF":2.0000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2026.2655477","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Survival for individuals with sickle cell disease (SCD) is increasing, and along with it the potential for comorbid conditions that may be caused by cumulative tissue damage. This paper examines the prevalence of comorbidities among individuals with SCD in Indiana and assesses how these vary by age group.

Methods: Data from the Indiana Sickle Cell Data Collection program (2015-2021) were used to identify confirmed and probable SCD cases. Comorbidities-asthma, avascular necrosis, stroke, retinopathy, moyamoya disease, and sickle nephropathy-were identified using ICD-9/10 codes.

Results: Among the 1689 individuals, the 0-17 age group was the largest (42.9%). Asthma was the most common comorbidity (23.7%), highest in the 18-39 age group. Avascular necrosis, stroke, and retinopathy increased with age, while moyamoya was most common in youth. Logistic regression showed increasing age was associated with the risk of any comorbidity risk.

Discussion: This study confirmed a high comorbidity burden among individuals with SCD, and that the risk of having any of the examined comorbidities increased with age. Findings align with national data, though differences in asthma and stroke prevalence highlight the impact of data sources and population characteristics.

Conclusion: These results support the need for age-specific, multidisciplinary care strategies and provide valuable insights for clinicians, policymakers, and public health officials to improve outcomes and allocate resources effectively for the SCD population.

印第安纳州镰状细胞数据收集(in - scdc)中按年龄划分的镰状细胞病合并症
目的:镰状细胞病(SCD)患者的生存率正在增加,同时伴有累积组织损伤引起的合并症的可能性也在增加。本文研究了印第安纳州SCD患者合并症的患病率,并评估了这些合并症如何随年龄组而变化。方法:使用印第安纳州镰状细胞数据收集计划(2015-2021)的数据来识别确诊和可能的SCD病例。合并症——哮喘、缺血性坏死、中风、视网膜病变、烟雾病和镰状肾病——使用ICD-9/10代码进行鉴定。结果:在1689只个体中,0 ~ 17岁年龄组最多,占42.9%;哮喘是最常见的合并症(23.7%),在18-39岁年龄组中最高。缺血性坏死、中风和视网膜病变随着年龄的增长而增加,而烟雾病在年轻人中最常见。逻辑回归显示年龄增加与任何合并症风险相关。讨论:本研究证实了SCD患者的高合并症负担,并且随着年龄的增长,任何被检查的合并症的风险都增加了。研究结果与国家数据一致,尽管哮喘和中风患病率的差异突出了数据来源和人口特征的影响。结论:这些结果支持了针对特定年龄的多学科护理策略的必要性,并为临床医生、政策制定者和公共卫生官员提供了有价值的见解,以改善SCD人群的预后和有效分配资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hematology
Hematology 医学-血液学
CiteScore
2.60
自引率
5.30%
发文量
140
审稿时长
3 months
期刊介绍: Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书